Correction to: CD163+CD14+ macrophages, a potential immune biomarker for malignant pleural effusion (Cancer Immunology, Immunotherapy, (2015), 64, 8, (965-976), 10.1007/s00262-015-1701-9);CD163+CD14+ macrophages, a potential immune biomarker for malignant pleural effusion

Cancer Immunology, Immunotherapy

Volumn 64, Issue 8, 2015, Pages 965-976

  Wang, Fei ^a,b   Yang, Li ^a   Gao, Qun ^a   Huang, Lan ^a   Wang, Liping ^a   Wang, Jing ^a   Wang, Shengdian ^c   Zhang, Bin ^d   Zhang, Yi ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

^c INSTITUTE OF BIOPHYSICS   (China)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Biomarker; CD163; Diagnosis; Malignant pleural effusion; Tumor associated macrophage

Indexed keywords

CD14 ANTIGEN; CD163 ANTIGEN; CYTOKINE; TUMOR MARKER; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ADULT; ARTICLE; BLOOD SAMPLING; CYTOLOGY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MALIGNANT PLEURA EFFUSION; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE; TUMOR ASSOCIATED LEUKOCYTE; VALIDATION STUDY; CELL SEPARATION; DIFFERENTIAL DIAGNOSIS; IMMUNOLOGY; IMMUNOPHENOTYPING; LABORATORY DIAGNOSIS; MACROPHAGE; METABOLISM; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT;

ANTIGENS, CD; ANTIGENS, CD14; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CELL SEPARATION; CYTOKINES; DIAGNOSIS, DIFFERENTIAL; FALSE POSITIVE REACTIONS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; MACROPHAGES; MALE; MIDDLE AGED; MONOCYTES; PLEURAL EFFUSION, MALIGNANT; RECEPTORS, CELL SURFACE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84937966910     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-021-03023-1     Document Type: Erratum

References (45)

1. Heffner JE, Klein JS (2008) Recent advances in the diagnosis and management of malignant pleural effusions. Mayo Clin Proc 83:235–250. doi:10.4065/83.2.235
2. Stathopoulos GT (2011) Translational advances in pleural malignancies. Respirology 16:53–63. doi:10.1111/j.1440-1843.2010.01890.x
3. Mishra EK, Davies RJ (2010) Advances in the investigation and treatment of pleural effusions. Expert Rev Respir Med 4:123–133
4. Morgensztern D, Waqar S, Subramanian J, Trinkaus K, Govindan R (2012) Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer. J Thorac Oncol 7:1485–1489. doi:10.1097/JTO.0b013e318267223a
5. Salah S, Tanvetyanon T, Abbasi S (2012) Metastatectomy for extra-cranial extra-adrenal non-small cell lung cancer solitary metastases: Systematic review and analysis of reported cases. Lung Cancer 75:9–14. doi:10.1016/j.lungcan.2011.07.014
6. Rakha EA, Patil S, Abdulla K, Abdulkader M, Chaudry Z, Soomro IN (2010) The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Diagn Cytopathol 38:874–879. doi:10.1002/dc.21303
7. Rodriguez-Panadero F, Romero-Romero B (2013) Current and future options for the diagnosis of malignant pleural effusion. Expert Opin Med Diagn 7:275–287. doi:10.1517/17530059.2013.786038
8. Basak SK, Veena MS, Oh S, Huang G, Srivatsan E, Huang M, Sharma S, Batra RK (2009) The malignant pleural effusion as a model to investigate intratumoral heterogeneity in lung cancer. PLoS ONE 4:e5884. doi:10.1371/journal.pone.0005884
9. Stathopoulos GT, Kalomenidis I (2012) Malignant pleural effusion: Tumor-host interactions unleashed. Am J Respir Crit Care Med 186:487–492. doi:10.1164/rccm.201203-0465PP
10. Ruffell B, Affara NI, Coussens LM (2012) Differential macrophage programming in the tumor microenvironment. Trends Immunol 33:119–126. doi:10.1016/j.it.2011.12.001
11. Coffelt SB, Hughes R, Lewis CE (2009) Tumor-associated macrophages: Effectors of angiogenesis and tumor progression. Biochim Biophys Acta 1796:11–18. doi:10.1016/j.bbcan.2009.02.004
12. Rogers TL, Holen I (2011) Tumour macrophages as potential targets of bisphosphonates. J Transl Med 9:177. doi:10.1186/1479-5876-9-177
13. Edin S, Wikberg ML, Dahlin AM, Rutegard J, Oberg A, Oldenborg PA, Palmqvist R (2012) The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS ONE 7:e47045. doi:10.1371/journal.pone.0047045
14. Chen C, Zhu YB, Shen Y, Zhu YH, Zhang XG, Huang JA (2012) Increase of circulating B7-H4-expressing CD68+ macrophage correlated with clinical stage of lung carcinomas. J Immunother 35:354–358. doi:10.1097/CJI.0b013e31824212c4
15. Komohara Y, Niino D, Saito Y, Ohnishi K, Horlad H, Ohshima K, Takeya M (2013) Clinical significance of CD163(+) tumor-associated macrophages in patients with adult T-cell leukemia/lymphoma. Cancer Sci 104:945–951. doi:10.1111/cas.12167
16. Reinartz S, Schumann T, Finkernagel F, Wortmann A, Jansen JM, Meissner W, Krause M, Schworer AM, Wagner U, Muller-Brusselbach S, Muller R (2014) Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: Correlation of CD163 expression, cytokine levels and early relapse. Int J Cancer 134:32–42. doi:10.1002/ijc.28335
17. de Vos van Steenwijk PJ, Ramwadhdoebe TH, Goedemans R, Doorduijn EM, van Ham JJ, Gorter A, van Hall T, Kuijjer ML, van Poelgeest MI, van der Burg SH, Jordanova ES (2013) Tumor-infiltrating CD14-positive myeloid cells and CD8-positive T-cells prolong survival in patients with cervical carcinoma. Int J Cancer 133:2884–2894. doi:10.1002/ijc.28309
18. Barros MH, Hassan R, Niedobitek G (2012) Tumor-associated macrophages in pediatric classical Hodgkin lymphoma: Association with Epstein–Barr virus, lymphocyte subsets, and prognostic impact. Clin Cancer Res 18:3762–3771. doi:10.1158/1078-0432.ccr-12-0129
19. Obermajer N, Wong JL, Edwards RP, Chen K, Scott M, Khader S, Kolls JK, Odunsi K, Billiar TR, Kalinski P (2013) Induction and stability of human Th17 cells require endogenous NOS2 and cGMP-dependent NO signaling. J Exp Med 210:1433–1445. doi:10.1084/jem.20121277
20. Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, Huflejt M, Carbone M, Chia D, Goodglick L, Goodman GE, Thornquist MD, Liu G, de Perrot M, Tsao MS, Goparaju C (2012) Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 367:1417–1427. doi:10.1056/NEJMoa1115050
21. Komohara Y, Jinushi M, Takeya M (2014) Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci 105:1–8. doi:10.1111/cas.12314
22. Shirabe K, Mano Y, Muto J, Matono R, Motomura T, Toshima T, Takeishi K, Uchiyama H, Yoshizumi T, Taketomi A, Morita M, Tsujitani S, Sakaguchi Y, Maehara Y (2012) Role of tumor-associated macrophages in the progression of hepatocellular carcinoma. Surg Today 42:1–7. doi:10.1007/s00595-011-0058-8
23. Pettersen JS, Fuentes-Duculan J, Suarez-Farinas M, Pierson KC, Pitts-Kiefer A, Fan L, Belkin DA, Wang CQ, Bhuvanendran S, Johnson-Huang LM, Bluth MJ, Krueger JG, Lowes MA, Carucci JA (2011) Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated. J Invest Dermatol 131:1322–1330. doi:10.103/jid.2011.9
24. Capece D, Fischietti M, Verzella D, Gaggiano A, Cicciarelli G, Tessitore A, Zazzeroni F, Alesse E (2013) The inflammatory microenvironment in hepatocellular carcinoma: A pivotal role for tumor-associated macrophages. Biomed Res Int 2013:187204. doi:10.1155/2013/187204
25. Walter RB, Bachli EB, Schaer DJ, Ruegg R, Schoedon G (2003) Expression of the hemoglobin scavenger receptor (CD163/HbSR) as immunophenotypic marker of monocytic lineage in acute myeloid leukemia. Blood 101:3755–3756. doi:10.1182/blood-2002-11-3414
26. Garcia C, Gardner D, Reichard KK (2008) CD163: A specific immunohistochemical marker for acute myeloid leukemia with monocytic differentiation. Appl Immunohistochem Mol Morphol 16:417–421. doi:10.1097/PAI.0b013e31815db477
27. Lau SK, Chu PG, Weiss LM (2004) CD163: A specific marker of macrophages in paraffin-embedded tissue samples. Am J Clin Pathol 122:794–801. doi:10.1309/qhd6-yfn8-1kqx-uuh6
28. Chung FT, Lee KY, Wang CW, Heh CC, Chan YF, Chen HW, Kuo CH, Feng PH, Lin TY, Wang CH, Chou CL, Chen HC, Lin SM, Kuo HP (2012) Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer. Int J Cancer 131:E227–E235. doi:10.1002/ijc.27403
29. Ma J, Liu L, Che G, Yu N, Dai F, You Z (2010) The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 10:112. doi:10.1186/1471-2407-10-112
30. Behnes CL, Bremmer F, Hemmerlein B, Strauss A, Strobel P, Radzun HJ (2014) Tumor-associated macrophages are involved in tumor progression in papillary renal cell carcinoma. Virchows Arch 464:191–196. doi:10.1007/s00428-013-1523-0
31. Santoni M, Massari F, Amantini C, Nabissi M, Maines F, Burattini L, Berardi R, Santoni G, Montironi R, Tortora G, Cascinu S (2013) Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 62:1757–1768. doi:10.1007/s00262-013-1487-6
32. Helm O, Held-Feindt J, Grage-Griebenow E, Reiling N, Ungefroren H, Vogel I, Kruger U, Becker T, Ebsen M, Rocken C, Kabelitz D, Schafer H, Sebens S (2014) Tumor-associated macrophages exhibit pro- and anti-inflammatory properties by which they impact on pancreatic tumorigenesis. Int J Cancer 135:843–861. doi:10.1002/ijc.28736
33. Lim MH, Garrettc J, Mowlem L, Yap E (2013) Diagnosing malignant pleural effusions: How do we compare? N Z Med J 126:42–48
34. Gorgun D, Secik F, Midilli K, Akkaya V, Yildiz P (2013) Diagnostic and prognostic significance of survivin levels in malignant pleural effusion. Respir Med 107:1260–1265. doi:10.1016/j.rmed.2013.04.011
35. Neumann V, Loseke S, Nowak D, Herth FJ, Tannapfel A (2013) Malignant pleural mesothelioma: Incidence, etiology, diagnosis, treatment, and occupational health. Dtsch Arztebl Int 110:319–326. doi:10.3238/arztebl.2013.0319
36. Rieux C, Boisdron-Celle M, Morel A, Fey L, Urban T, Hureaux J (2013) Biological diagnosis of resistance to erlotinib in a malignant pleural effusion. Rev Mal Respir 30:572–575. doi:10.1016/j.rmr.2013.02.010
37. Johnston WW (1985) The malignant pleural effusion. A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer 56:905–909
38. Sriram KB, Relan V, Clarke BE, Duhig EE, Windsor MN, Matar KS, Naidoo R, Passmore L, McCaul E, Courtney D, Yang IA, Bowman RV, Fong KM (2012) Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas. BMC Cancer 12:428. doi:10.1186/1471-2407-12-428
39. Kaczmarek M, Sikora J (2012) Macrophages in malignant pleural effusions - alternatively activated tumor associated macrophages. Contemp Oncol (Pozn) 16:279–284. doi:10.5114/wo.2012.30054
40. Mundt F, Heidari-Hamedani G, Nilsonne G, Metintas M, Hjerpe A, Dobra K (2014) Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies. Biomed Res Int 2014:419853. doi:10.1155/2014/419853
41. Xu C, Yu L, Zhan P, Zhang Y (2014) Elevated pleural effusion IL-17 is a diagnostic marker and outcome predictor in lung cancer patients. Eur J Med Res 19:23. doi:10.1186/2047-783x-19-23
42. Gong Y, Chen SX, Gao BA, Yao RC, Guan L (2014) Cell origins and significance of IL-17 in malignant pleural effusion. Clin Transl Oncol 16:807–813. doi:10.1007/s12094-013-1152-8
43. Gonda K, Shibata M, Shimura T, Abe N, Suzuki S, Yasuda M, Nakamura I, Ohtake T, Ohki S, Watanabe T, Fujimori K, Ohto H, Takenoshita S (2012) Changes in myeloid-derived suppressor cells in malignant effusions of cancer patients following cancer chemotherapy. Gan To Kagaku Ryoho 39:2088–2091
44. Romano A, Parrinello NL, Vetro C, Forte S, Chiarenza A, Figuera A, Motta G, Palumbo GA, Ippolito M, Consoli U, Raimondo FD (2015) Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin lymphoma patients treated up-front with a risk-adapted strategy. Br J Haematol 168:689–700. doi:10.1111/bjh.13198
45. Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, Robinson SC, Balkwill FR (2008) “Re-educating” tumor-associated macrophages by targeting NF-kappaB. J Exp Med 205:1261–1268. doi:10.1084/jem.20080108